KORU Medical Systems Business Summary

KORU Medical Systems (KRMD) operates a specialized medical technology business model focused on the development and commercialization of large-volume subcutaneous infusion solutions. The company generates revenue primarily through the sale of its proprietary Freedom Infusion Systems—including the FREEDOM60 and FreedomEdge syringe drivers—and high-margin, recurring sales of consumables such as precision flow rate tubing and HIgH-Flo safety needle sets. Business operations are bifurcated into two strategic segments: the core Immunoglobulin (Ig) business, which serves a growing base of chronic patients requiring home-based therapy for primary immunodeficiencies, and the Pharma Services and Clinical Trials division, which partners with biopharmaceutical firms to integrate KORU’s delivery platforms with novel biologics and oncology treatments. In the competitive landscape, KORU competes with diversified medical giants like Medtronic and B. Braun, as well as niche subcutaneous specialists such as EMED and Zyno Medical. KORU maintains a leading market position in the home-infusion niche by leveraging its mechanical, constant-pressure technology, which offers a simpler and more cost-effective alternative to complex electronic infusion pumps. Originally founded in 1980 by Andrew Sealfon, the company is currently led by President and CEO Linda Tharby, who joined in 2021 after a 24-year career at Becton Dickinson (BD), where she was instrumental in scaling the firm into an $18 billion global leader. The executive suite includes CFO Tom Adams, a veteran of Integra LifeSciences and Pfizer, and Chief Commercial Officer Adam Kalbermatten, who joined in July 2025 from BD to drive international growth. In December 2025, the team was further bolstered by the appointment of Eric Schiller as Chief Technology Officer, bringing over 25 years of experience from Sanofi to lead the company’s expansion into oncology and drug-device combination products. Strategic oversight is provided by Chairman R. John Fletcher, founder of Fletcher Spaght, and the board features Joseph M. Manko Jr., a significant shareholder through Horton Capital Management. This leadership team is currently executing 'Vision 2026,' a strategic roadmap aimed at diversifying KORU’s clinical applications beyond its traditional Ig stronghold into the broader biologics market.